{"id":551149,"date":"2025-11-22T10:59:12","date_gmt":"2025-11-22T10:59:12","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/551149\/"},"modified":"2025-11-22T10:59:12","modified_gmt":"2025-11-22T10:59:12","slug":"chez-ladolescent-le-prozac-ne-fait-pas-mieux-quun-placebo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/551149\/","title":{"rendered":"chez l\u2019adolescent, le Prozac ne fait pas mieux qu&rsquo;un placebo"},"content":{"rendered":"<p>    La fluox\u00e9tine (Prozac et g\u00e9n\u00e9riques) est en France le seul antid\u00e9presseur ayant une autorisation de mise sur le march\u00e9 dans le traitement de la d\u00e9pression chez les patients de moins de 18 ans.<br \/>\n                fizkes &#8211; stock.adobe.com<\/p>\n<p>\n    Faut-il, chez l\u2019enfant et l\u2019adolescent, jeter cet antid\u00e9presseur aux orties\u00a0? Des chercheurs s\u2019interrogent sur son maintien dans les recommandations internationales.<\/p>\n<p class=\"fig-paragraph\">Les adolescents\u00a0<a href=\"http:\/\/sante.lefigaro.fr\/psychologie\/la-deterioration-de-la-sante-mentale-chez-les-jeunes-etait-amorcee-avant-le-covid-mais-s-est-accentuee-20250130\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\" rel=\"nofollow noopener\" target=\"_blank\">vont-ils de plus en plus mal<\/a>, ou\u00a0<a href=\"http:\/\/www.lefigaro.fr\/conjoncture\/sante-mentale-quand-la-culture-populaire-aide-a-liberer-la-parole-20241217\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\" rel=\"nofollow noopener\" target=\"_blank\">en parlent-ils plus volontiers<\/a>\u00a0? Toujours est-il qu\u2019ils sont\u00a0<a href=\"http:\/\/www.lefigaro.fr\/actualite-france\/sante-mentale-les-ados-sont-davantage-alles-aux-urgences-apres-un-geste-ou-des-idees-suicidaires-en-septembre-20241010\" data-fig-type=\"Article\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"LEFIGARO\" rel=\"nofollow noopener\" target=\"_blank\">de plus en plus nombreux \u00e0 \u00eatre pris en charge<\/a>\u00a0pour des troubles psychiques, et notamment\u00a0<a href=\"https:\/\/sante.lefigaro.fr\/sante\/maladie\/depression\/quels-traitements\" target=\"_blank\" data-fig-type=\"Keyword\" rel=\"sponsored noopener nofollow\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\" data-fig-domain=\"SANTE\">d\u00e9pressifs<\/a>. Or, du diagnostic \u00e0 la gu\u00e9rison, un adolescent d\u00e9pressif ne se soigne pas comme un adulte. En particulier concernant les m\u00e9dicaments\u00a0: si un antid\u00e9presseur peut \u00eatre prescrit d\u2019embl\u00e9e chez l\u2019adulte, chez l\u2019enfant et l\u2019adolescent, il ne doit \u00eatre envisag\u00e9 que lorsque tout le reste a \u00e9chou\u00e9.<\/p>\n<p class=\"fig-paragraph\">Et pour cause\u00a0: le Prozac (dont la mol\u00e9cule active\u00a0est la fluox\u00e9tine), seul antid\u00e9presseur autoris\u00e9 en France dans la d\u00e9pression chez l\u2019enfant et l\u2019adolescent, ne serait \u00ab\u00a0pas plus efficace qu\u2019un placebo\u00a0\u00bb dans cette population, ass\u00e8nent des chercheurs britanniques et autrichiens\u00a0<a href=\"https:\/\/www.jclinepi.com\/article\/S0895-4356%2825%2900349-X\/fulltext\" target=\"_blank\" rel=\"sponsored noopener nofollow\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\">dans le Journal of Clinical Epidemiology<\/a> . Ils rappellent notamment\u00a0les r\u00e9sultats d\u2019<a href=\"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD013674.pub2\/epdf\/full\" target=\"_blank\" rel=\"sponsored noopener nofollow\" data-gtm-custom-categorie=\"navigation\" data-gtm-custom-action=\"crossclick\" data-gtm-custom-label=\"Contextuel\" data-gtm-event=\"customEventSPE\">une m\u00e9ta analyse de la collaboration Cochrane de 2021.\u00a0<\/a>Et s\u2019interrogent\u00a0: pourquoi cet antid\u00e9presseur commercialis\u00e9\u2026<\/p>\n<p class=\"fig-premium-paywall__infos\">\n        Cet article est r\u00e9serv\u00e9 aux abonn\u00e9s.        Il vous reste 84% \u00e0 d\u00e9couvrir.\n    <\/p>\n<p>                <img  data- alt=\"Le Figaro\" class=\"fig-img--complete fig-img\"\/><\/p>\n<p class=\"fig-premium-paywall__title\">Black Friday<\/p>\n<p class=\"fig-premium-paywall__subtitle\">-70% sur l&rsquo;abonnement num\u00e9rique<\/p>\n<p class=\"fig-premium-paywall__connect\">\n                D\u00e9j\u00e0 abonn\u00e9\u00a0?                <a class=\"fig-premium-paywall__connect-link\" href=\"https:\/\/connect.lefigaro.fr\/login?client=sante_web&amp;type=main&amp;redirect_uri=https%3A%2F%2Fsante.lefigaro.fr%2Fmedecine%2Fdepression-chez-l-adolescent-le-prozac-ne-fait-pas-mieux-qu-un-placebo-20251122\" data-js-gtm=\"{&quot;customCategorie&quot;: &quot;conversion&quot;, &quot;customAction&quot;: &quot;before_Landing_Connexion_paywall_auto&quot;, &quot;customLabel&quot;: &quot;c2FudGUubGVmaWdhcm8uZnJfXzFmMGM2MzE1LWIzOGEtNmZlNi05NDIxLWYzNDY4YmMyOTBmOF9fQXJ0aWNsZQ==_D\u00e9pression\u00a0: chez l\u2019adolescent, le Prozac ne fait pas mieux qu&#039;un placebo_488&quot;, &quot;customIDSPE&quot;: &quot;c2FudGUubGVmaWdhcm8uZnJfXzFmMGM2MzE1LWIzOGEtNmZlNi05NDIxLWYzNDY4YmMyOTBmOF9fQXJ0aWNsZQ==&quot;, &quot;event&quot;: &quot;customEventSPE&quot;}\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n                    Connectez-vous<br \/>\n                <\/a>\n            <\/p>\n","protected":false},"excerpt":{"rendered":"La fluox\u00e9tine (Prozac et g\u00e9n\u00e9riques) est en France le seul antid\u00e9presseur ayant une autorisation de mise sur le&hellip;\n","protected":false},"author":2,"featured_media":551150,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[124,2073,1011,27,72,236,61461,71],"class_list":{"0":"post-551149","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-sante","8":"tag-antidepresseurs","9":"tag-depression","10":"tag-fr","11":"tag-france","12":"tag-health","13":"tag-pediatrie","14":"tag-prozac","15":"tag-sante"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115593004023276788","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/551149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=551149"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/551149\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/551150"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=551149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=551149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=551149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}